Verici Dx plc (AIM:VRCI)
London · Delayed Price · Currency is GBP · Price in GBX 0.2250
0.00 (0.00%)
Sep 11, 2026, 3:44 PM GMT
Verici Dx Employees
Verici Dx had 18 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
18
Change
n/a
Growth
n/a
Revenue / Employee
151.24K GBP
Profits / Employee
-286.18K GBP
Market Cap
5.15M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 18 | 0 | - |
| Dec 31, 2024 | 18 | 4 | 28.57% |
| Dec 31, 2023 | 14 | -1 | -6.67% |
| Dec 31, 2022 | 15 | 5 | 50.00% |
| Dec 31, 2021 | 10 | 2 | 25.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 96,100 |
| GSK plc | 66,841 |
| Haleon | 24,535 |
| Smith & Nephew | 17,000 |
| GENinCode | 44 |
| Proteome Sciences | 32 |
| Theracryf | 9 |
| Cizzle Biotechnology Holdings | 5 |
Verici Dx News
- 2 months ago - Verici Dx Earnings Call Transcript: H2 2025 - Transcripts
- 2 months ago - Verici Dx Annual report: H2 2025 - Filings
- 2 months ago - Verici Dx Annual report: H2 2025 - Filings
- 2 months ago - Verici Dx Slides: H2 2025 - Filings
- 2 months ago - Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection Test - Business Wire
- 2 months ago - Verici Dx Collaborators to Present Data on Predictive Value of Tutivia™ for Acute Kidney Transplant Rejection at ATC 2026 - Business Wire
- 3 months ago - CORRECTING and REPLACING Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients - Business Wire
- 3 months ago - Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients - Business Wire